Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

Stefanini, B; Bucci, L; Santi, V; Reggidori, N; Rampoldi, D; Lani, L; Granito, A; Sangiovanni, A; Cabibbo, G; Farinati, F; Campani, C; Foschi, FG; Svegliati-Baroni, G; Raimondo, G; Gasbarrini, A; Mega, A; Biasini, E; Sacco, R; Morisco, F; Caturelli, E; Vidili, G; Azzaroli, F; Giannini, EG; Rapaccini, GL; Brunetto, MR; Masotto, A; Nardone, G; Di Marco, M; Magalotti, D; Trevisani, F; Italian Liver Canc ITALICA Grp

Trevisani, F (通讯作者)，IRCCS Azienda Osped Univ Bologna, Unit Semeiot Liver & Alcohol related Dis, Bologna, Italy.

DIGESTIVE AND LIVER DISEASE, 2022; 54 (11): 1563

Abstract

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular c......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索